A randomized phase II trial of oral topotecan versus docetaxel in the second-line treatment of non-small-cell lung cancer

Clinical Lung Cancer

Volumn 9, Issue 3, 2008, Pages 154-159

  Jones, Suzanne ^a   Thompson, Dana ^a   Barton, John ^a   Patton, Jeff ^a   Shipley, Dianna ^a   Greco, F Anthony ^a   Spigel, David ^a   Infante, Jeff ^a   Burris III, Howard A ^a  

^a SARAH CANNON RESEARCH INSTITUTE   (United States)

Author keywords

Creatinine clearance; Myelosuppression; Thrombocytopenia; Topoisomerase I inhibitors

Indexed keywords

BEVACIZUMAB; DOCETAXEL; ERLOTINIB; ETOPOSIDE; GEFITINIB; GEMCITABINE; LAPATINIB; NAVELBINE; TAXANE DERIVATIVE; TOPOTECAN;

ADULT; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTHRALGIA; ARTICLE; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPHAGIA; EDEMA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HAND FOOT SYNDROME; HEMOPTYSIS; HUMAN; LACRIMATION; LIVER FUNCTION TEST; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MYALGIA; NAIL DISEASE; NAUSEA; NEUROPATHY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RASH; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; VOMITING; WEAKNESS;

EID: 45849153914     PISSN: 15257304     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLC.2008.n.023     Document Type: Article

References (14)

1. Shepherd FA, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000; 18:2095-103.
2. Fosella FV, DeVore R, Kerr R, et al, on behalf of the TAX320 Non-Small Cell Lung Cancer Study Group. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small cell lung cancer previously treated with platinum-containing chemotherapy regimens. J Clin Oncol 2000; 18:2354-62.
3. Perez-Soler R, Fosella FV, Glisson BS, et al. Phase II study of topotecan in patients with advanced non-small cell lung cancer previously untreated with chemotherapy. J Clin Oncol 1996; 14:503-13.
4. Kindler HL, Kris MG, Smith IE, et al. Phase II trial of topotecan administered as a 21-day continuous infusion in previously untreated patients with stage IIIB and IV non-small cell lung cancer. Am J Clin Oncol 1998; 21:438-41.
5. White SC, Cheeseman S, Thatcher N, et al. Phase II study of oral topotecan in advanced non-small cell lung cancer. Clin Cancer Res 2000; 6:868-73.
6. Jones SF, Kuhn JG, Greco FA, et al. Prolonged intermittent oral topotecan in patients with refractory and/or advanced malignancies: a phase I study. Am J Cancer 2004; 3:317-24.
7. Green S, Weiss GR. Southwest Oncology Group standard response criteria, endpoint definitions, and toxicity criteria. Invest New Drugs 1992; 10:239-53.
8. Simon R. Optimal two-stage designs for phase II clinical trials. Controlled Clin Trials 1989; 10:1-10.
9. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53:457-81.
10. StataCorp. 2003. Stata Statistical Software: Release 8.0. College Station TSC.
11. Ramlau R, Gervais R, Krzakowski M, et al. Phase III study comparing oral topotecan to intravenous docetaxel in patients with pretreated advanced non-small-cell lung cancer. J Clin Oncol 2006; 24:2800-7.
12. Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004; 22:1589-97.
13. Shepherd FA, Rodrigues Pereira J, Ciuleanu T et al. Erlotinib in previously treated non-small cell lung cancer. N Engl J Med 1005; 353:123-32.
14. Sequist LV, Bell DW, Lynch TJ, et al. Molecular predictors of response to epidermal growth factor receptor antagonists in non-small cell lung cancer. J Clin Oncol 2007; 25:587-95.